Biosensors International has announced the enrolment of the first patient in the BIOMICS study, a prospective, multicentre evaluation of the safety and effectiveness of the Biosensors Microcatheter in patients undergoing percutaneous coronary intervention (PCI) for the treatment of chronic total occlusions (CTO).
Biosensors are conducting BIOMICS as part of their product development activities for the new coronary microcatheter. The trial will include up to 10 sites in the UK and is being conducted under the leadership of Margaret McEntegart (Golden Jubilee National Hospital, Glasgow, UK) and James Spratt (St George’s Hospital, London, UK).
Biosensors chief medical officer, Keith G Oldroyd, said: “We are confident that this new microcatheter design will help interventional cardiologists to further improve the already excellent results they are achieving in CTO-PCI.”
Margaret McEntegart and Aadil Shaukat enrolled the first BIOMICS patients at the Golden Jubilee National Hospital in Glasgow. “We are very excited to have performed the first in human cases with the new microcatheter from Biosensors as part of the BIOMICS study here at GJNH. The new microcatheter was successful in crossing the CTO with no complications. We look forward to recruiting more patients in coming weeks.”
